Sixth, the observed relationship between SGLT‐2 inhibitor use and improved outcomes supports the earlier introduction of these agents in patients with CAD and type 2 DM, beyond their traditional role in glycemic control. This evidence concerns the gene SLC5A2 and coronary artery disorder.